sulpiride has been researched along with n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brownings, S; Clark-Papasavas, C; Cleij, M; Dunn, JT; Gomes, R; Greaves, S; Howard, R; Joemon, J; Kessler, R; Liu, K; Marsden, P; Mogg, A; Nwosu, B; Reeves, S | 1 |
| Seeman, P | 1 |
| Bertrand, J; Brownings, S; D'Antonio, F; Dunn, J; Greaves, S; Howard, R; Kessler, R; Marsden, P; McLachlan, E; Nair, A; Reeves, S; Smith, A; Taylor, D | 1 |
1 trial(s) available for sulpiride and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide
| Article | Year |
|---|---|
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Dopamine Agents; Female; Humans; Male; Positron-Emission Tomography; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Socioeconomic Factors; Sulpiride; Treatment Outcome | 2017 |
2 other study(ies) available for sulpiride and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide
| Article | Year |
|---|---|
Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Brain Mapping; Female; Humans; Male; Positron-Emission Tomography; Psychotic Disorders; Receptors, Dopamine D2; Sulpiride | 2014 |
Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer's disease.
Topics: Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Brain Mapping; Female; Humans; Male; Positron-Emission Tomography; Psychotic Disorders; Receptors, Dopamine D2; Sulpiride | 2014 |